ViaCyte
San Diego, US · Delaware corporation · 7 known investors
Find your way into ViaCyte
Transforming the lives of patients through a functional cure for Type 1 Diabetes
Founders & leadership
BB
Brittany BradrickExecutive
AS
Anne SandanExecutive
EB
Elizabeth BuiExecutive
SW
Steve WhiteExecutive
HF
Howard FoytinSenior Medical Advisor
KD
MS
Michael ScottExecutive
PL
Paul LaikindExecutive
Board
AZ
LI
Lucian IancoviciBoard director
FA
DJ
Donald J. ElmerBoard director
Investors · 7
Artis VenturesSan Francisco · $50K – $25M
Bain Capital Life SciencesBoston
RA CapitalBoston
Sanderling VenturesSan Mateo · $50K – $1M
The Vertical GroupBerkeley Heights · $250K – $5M
Red Tree VenturereportedSan Diegovia Heath Lukatch · board
Also in the syndicate · 1
Breakthrough T1D
Reported raises · per SEC filings
Form D private placements$137.4M disclosed across 4 rounds · 2014–2021
▶$53.9MraisedApr 2021 · 22 investors · BiotechnologyRule 506(b)
▶$53.9MraisedApr 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Amir ZamaniDirector
- Brittany BradrickExecutive Officer
- Sandra PooleDirector
- Anne SandanExecutive Officer
- Elizabeth BuiExecutive Officer
- Lucian IancoviciDirector
- Steve WhiteExecutive Officer
- Fred A. MiddletonDirector
- Mark G. FolettaDirector
- Howard FoytExecutive Officer
- Paul HastingsDirector
- Steven R. AltmanDirector
- Ian SmithDirector
- Kevin D'AmourExecutive Officer
- Asish XavierDirector
- Michael YangExecutive Officer, Director
- Offering amount
- $58.5M
- Amount sold
- $53.9M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$32.6MraisedApr 2020 · 17 investors · BiotechnologyRule 506(b)
▶$32.6MraisedApr 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin D'AmourExecutive Officer
- Mark G. FolettaDirector
- Ian SmithDirector
- Adam KoppelDirector
- Asish XavierDirector
- Mark ZimmermanExecutive Officer
- Anne SandanExecutive Officer
- Liz BuiExecutive Officer
- Steve KradjianExecutive Officer
- Paul HastingsDirector
- Howard FoytExecutive Officer
- Steven R. AltmanDirector
- Paul LaikindExecutive Officer, Director
- Fred A. MiddletonDirector
- Sandra PooleDirector
- Heath LukatchDirector
- Offering amount
- $36M
- Amount sold
- $32.6M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.8MraisedDec 2018 · 9 investors · BiotechnologyRule 506(b)
▶$35.8MraisedDec 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Asish XavierDirector
- Steven R. AltmanDirector
- Paul LaikindExecutive Officer, Director
- Anne SandanExecutive Officer
- Mark G. FolettaDirector
- Elizabeth BuiExecutive Officer
- Adam KoppelDirector
- Heath LukatchDirector
- Howard FoytExecutive Officer
- Kevin D'AmourExecutive Officer
- Fred A. MiddletonDirector
- Offering amount
- $90M
- Amount sold
- $35.8M
- Sales commissions
- $2.7M
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedAug 2014 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedAug 2014 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Howard FoytExecutive Officer
- Fred A. MiddletonDirector
- Donald J. ElmerDirector
- Kevin D'AmourExecutive Officer
- Mark G. FolettaDirector
- Michael ScottExecutive Officer
- Elizabeth BuiExecutive Officer
- Paul LaikindExecutive Officer, Director
- Orville G. KoltermanDirector
- Anne SandanExecutive Officer
- Franklin P. JohnsonDirector
- Steven R. AltmanDirector
- Allan RobinsExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $954.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $644.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | $99.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does ViaCyte do?
- Transforming the lives of patients through a functional cure for Type 1 Diabetes
- Who are ViaCyte's investors?
- ViaCyte's investors include Artis Ventures, Bain Capital Life Sciences, RA Capital, Sanderling Ventures, The Vertical Group, Red Tree Venture.
- How much funding has ViaCyte raised?
- ViaCyte has disclosed $137.4M raised across 4 rounds.
- Where is ViaCyte headquartered?
- ViaCyte is headquartered in San Diego, US.